Healthcare / BiotechnologyNasdaqGS
$15.43
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-175.0%
↓Gross Margin
N/A
•Debt/Equity
1.86
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-2.9%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.72B · net income $-986.2M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $2.72B | $2.72B | $2.70B | $2.84B | $2.84B | $3.06B |
| Net Income | $-986.2M | $-986.2M | $-328.5M | $-25.2M | $186.2M | $98.0M |
| EBITDA | $-794.6M | $-794.6M | $-75.0M | $130.0M | $280.7M | $280.6M |
| EPS | -10.81 | -10.81 | -3.67 | -0.29 | 2.09 | 1.10 |
| Operating Margin | -32.0% | -32.0% | -6.0% | 1.1% | 6.6% | 3.7% |
| Net Margin | -36.2% | -36.2% | -12.2% | -0.9% | 6.6% | 3.2% |
| Balance Sheet | ||||||
| Debt/Equity | 1.86 | 1.86 | 0.77 | 0.91 | 0.00 | — |
| Returns | ||||||
| ROE | -175.0% | -175.0% | -24.1% | -1.5% | 5.6% | 3.0% |
| Growth & Yield | ||||||
| Revenue Growth | 1.0% | 1.0% | -5.1% | 0.2% | -7.2% | — |
| EPS Growth | -194.6% | -194.6% | -1165.5% | -113.9% | 90.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.